The US Food and Drug Administration (FDA) has granted fast track designation to ivonescimab for use in combination with platinum-based chemotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with an EGFR mutation, who have experienced disease progression following EGFR-TKI therapy.
https://finance.yahoo.com/news/summit-completes-subject-enrolment-phase-083234712.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.